These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 27436250)

  • 1. [Cervical cancer screening with primary HPV-DNA test in the Local Health Authority 2 of Savona (Liguria Region, Northern Italy): a population-based study].
    Depetrini E; Bonelli L; Ardoino S; Cirucca MC; Contin R; De Leonardis D; Errigo V; Lugani A; Franco A; Pastorino A; Carrozzi G; Venturino E
    Epidemiol Prev; 2016; 40(3-4):171-8. PubMed ID: 27436250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
    Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
    Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Suprasert P; Srisomboon J; Intaraphet S; Siriaunkgul S
    PLoS One; 2016; 11(6):e0158184. PubMed ID: 27336913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study.
    Zorzi M; Frayle H; Rizzi M; Fedato C; Rugge M; Penon MG; Bertazzo A; Callegaro S; Campagnolo M; Ortu F; Del Mistro A;
    BJOG; 2017 Sep; 124(10):1585-1593. PubMed ID: 28120382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indicators for monitoring screening programs with primary HPV test.
    Zorzi M; Giorgi Rossi P;
    Epidemiol Prev; 2017; 41(1 Suppl 1):1-32. PubMed ID: 28322534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
    Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
    Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cervical human papilloma virus (HPV) DNA primary screening test: Results of a population-based screening programme in central Italy.
    Passamonti B; Gustinucci D; Giorgi Rossi P; Cesarini E; Bulletti S; Carlani A; Martinelli N; Broccolini M; D'Angelo V; D'Amico MR; Di Dato E; Galeazzi P; Malaspina M; Spita N; Tintori B; Giaimo MD
    J Med Screen; 2017 Sep; 24(3):153-162. PubMed ID: 27614992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity level and process indicators of organised programmes for cervical cancer screening in Italy.
    Ronco G; Giubilato P; Naldoni C; Zorzi M; Anghinoni E; Scalisi A; Dalla Palma P; Zanier L; Federici A; Angeloni C; Prandini S; Maglietta R; Mancini E; Pizzuti R; Iossa A; Segnan N; Zappa M
    Epidemiol Prev; 2006; 30(1 Suppl 3):27-40. PubMed ID: 16937844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV screening performance indicators in women who previously tested HPV-negative: The second round of Vallecamonica screening programme, Northern Italy.
    Pasquale L; Rossi PG; Carozzi F; Domenighini S; Ruggeri C; Cecconami L; Morana C; Chiaramonte M; Chiudinelli D; Piccolomini M; Marchione R; Confortini M
    J Med Screen; 2020 Dec; 27(4):207-214. PubMed ID: 32102618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of diagnostic indicators of cervical cancer screening among women accessing through volunteer organisations and those via the organised programme in Turin (Piedmont Region, Northern Italy).
    Ferrante G; Castagno R; Rizzolo R; Armaroli P; Caprioglio A; Larato C; Giordano L
    Epidemiol Prev; 2020; 44(5-6 Suppl 1):115-123. PubMed ID: 33415954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical performance of high risk HPV DNA test among triage women with cytology showing atypical squamous cells of undetermined significance].
    Zhang SK; Zhao DM; Chen HM; Guo Z; Ren LY; Jia MM; Chang JJ; Chen PP; Liu SZ; Sun XB
    Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Sep; 52(9):941-945. PubMed ID: 30196643
    [No Abstract]   [Full Text] [Related]  

  • 15. hr-HPV testing in the management of women with ASC-US+ and in the follow-up of women with cytological abnormalities and negative colposcopy. Recommendations of the Italian group for cervical cancer screening (GISCi).
    Carozzi FM; Iossa A; Scalisi A; Sideri M; Andersson KL; Confortini M; Del Mistro A; Maina G; Ronco G; Raggi P; Schiboni ML; Zappa M; Giorgi Rossi P
    Epidemiol Prev; 2015; 39(3 Suppl 1):84-90. PubMed ID: 26405780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extension of organised cervical cancer screening programmes in Italy and their process indicators, 2009 activity.
    Ronco G; Giubilato P; Naldoni C; Zorzi M; Anghinoni E; Scalisi A; Dalla Palma P; Zanier L; Barca A; Angeloni C; Gaimo MD; Maglietta R; Mancini E; Pizzuti R; Iossa A; Segnan N; Zappa M
    Epidemiol Prev; 2011; 35(5-6 Suppl 5):39-54. PubMed ID: 22166349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Extension of organised cervical cancer screening programmes in Italy and their process indicators, 2010 activity].
    Ronco G; Giubilato P; Naldoni C; Zorzi M; Anghinoni E; Scalisi A; Dalla Palma P; Zanier L; Barca A; Angeloni C; Gaimo MD; Maglietta R; Mancini E; Pizzuti R; Iossa A; Segnan N; Zappa M
    Epidemiol Prev; 2012; 36(6 Suppl 1):39-54. PubMed ID: 23293270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [HPV primary test in the cervical cancer screening: reproducibility assessment and investigation on cytological outcome of Hybrid Capture 2 borderline samples].
    Burroni E; Sani C; Bisanzi S; Ocello C
    Epidemiol Prev; 2016; 40(3-4):164-70. PubMed ID: 27436249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.
    Cuzick J; Arbyn M; Sankaranarayanan R; Tsu V; Ronco G; Mayrand MH; Dillner J; Meijer CJ
    Vaccine; 2008 Aug; 26 Suppl 10():K29-41. PubMed ID: 18847555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
    Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.